Yuri Fedoriw, MD
Director, Global Cancer Pathology, Institute for Global Health and Infectious Diseases
LabCorp Distinguished Professor, Vice Chair of Clinical Research and Academic Affairs, Department of Pathology and Laboratory Medicine
Co-Director, UNC Project Malawi Cancer Program
Areas of Interest
cancer genetics and pathology, HIV-associated lymphomas, cancer clinical trials in LMICs
About
Since 2011, Dr. Feoriw has been involved in the UNC Project-Malawi Cancer Program, developing and supporting diagnostic services in support of the Kamuzu Central Hospital Lymphoma Study, AIDS Malignancy Consortium, and NIH-funded clinical trials. He now serves as the co-director of the UNC Project-Malawi Cancer Program, the co-PI of the UNC-Malawi-South Africa Cancer Consortium (U54CA254564), and directs the translational lymphoma studies of samples submitted to UNC through this ongoing work. He has established weekly diagnostic telepathology conferences between Malawian pathologists and clinical teams to improve diagnostic accuracy and build regional capacity for cancer care. He supports training in global cancer research through the recently awarded Malawi Cancer Outcomes Research Program (D43CA260641 Fedoriw, MPI) that aims to develop global cancer research leaders in Malawi and UNC. Dr. Feoriw’s research interests focus on the immunologic and genetic mechanisms of lymphomagenesis, particularly in the setting of HIV infection. While hematologic malignancies and lymphoproliferative disorders (including Multicentric Castleman Disease) in sub-Saharan Africa arise under intrinsic and extrinsic pressures very different from those in the United States, comprehensive analyses of these diseases have not been performed. His laboratory group uses advanced sequencing, immunophenotypic, and cellular analyses to address gaps in our understanding of lymphomagenesis and tumor microenvironment in the context of HIV-associated immune dysregulation. Deciphering these tumor-host interactions is critical to better tailor treatment and improve outcomes, particularly in the era of cancer immunotherapy.
Education
-
Undergraduate
John Carroll University
-
Medical School
Medical College of Ohio
-
Residency
Yale School of Medicine
-
Fellowship
Yale School of Medicine